In this paper the factors affecting the commercialization of ag-biotech products in Canada destined for international markets. Public acceptance issues, lack of internationally harmonized regulatory systems and data requirements, politicized regulatory systems, intellectual property rights, unclear and inconsistent labeling laws, and the current uncertainty cultivated by the United Nations Convention on Biological Diversity (CBD) Biosafety Protocol, all contribute to market access barriers for Genetically Modified Organisms (GMOs) are discussed.
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.